Ginkgo Bioworks, operating under the ticker $DNA, has partnered with Inductive Bio and Tangible Scientific to implement AI-driven lab-in-the-loop workflows aimed at accelerating drug discovery and development across the biopharma industry. This collaboration combines Ginkgo’s ADME profiling capabilities, Inductive Bio’s AI-driven chemistry design, and Tangible Scientific’s compound management system to reduce iteration times in drug development processes. The partnership addresses existing bottlenecks in drug design workflows, such as shipping, receiving, and lab testing, which have not been fully resolved by AI applications to date. Concurrently, advancements in AI for pharma include the development of rBio, an AI assistant trained on virtual cell models and real scientific data, designed to simulate biological processes and aid in disease research at the cellular level. Industry discussions continue around AI’s role in reducing clinical trial failure rates and preclinical costs, highlighting the growing integration of AI technologies in pharmaceutical research and development.